FDA says Novo Nordisk’s Oprah Winfrey video makes Wegovy, Ozempic and Victoza look safer than their labels allow.
What happened
FDA reviewed a 42-minute direct-to-consumer video, “An Oprah Special: Shame, Blame, and the Weight Loss Revolution,” about Wegovy, Ozempic, and Victoza. The video aired on ABC on March 18, 2024, later appeared on Hulu, and featured Novo Nordisk paid consultants and a sales executive. FDA found the video false or misleading because it omitted and downplayed serious risks, including a highlighted serious-risk warning, and because the promotional materials were not submitted when first published.
What FDA found
The video left out the boxed warning’s rule that people with a personal or family history of MEN 2, a rare endocrine condition, should not use these drugs because of thyroid cancer risk.
21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(5); (e)(7)(viii)The video omitted other serious risks listed in the label, including low blood sugar, acute kidney injury, allergic reactions, diabetic eye problems, increased heart rate, suicidal thoughts or behavior, and sharing a pen between patients.
21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(5); (e)(7)(viii)A paid consultant called pancreatitis, gallbladder complications, and thyroid cancer concerns “hype” and “very, very rare,” which FDA says wrongly minimized serious risks.
21 U.S.C. 352(a); 21 CFR 202.1(e)(5)A paid consultant said GLP-1 side effects were “overhyped” and “mild to moderate,” even though the label reports severe gastrointestinal reactions and discontinuations in trials.
21 CFR 202.1(e)(5); (e)(7)(viii)Novo Nordisk did not submit the promotional materials when they were first published, as required.
21 CFR 314.81(b)(3)(i)
What FDA wants
FDA says distribution of the video violates the law and calls for truthful, nonmisleading promotion of these drugs. The provided text does not state a response deadline.
Who should pay attention
- drugmakers that promote GLP-1 medicines
- medical and promotional review teams
- clinicians and patients choosing obesity or diabetes treatment
This is a summary. Read the original letter on fda.gov.